Glatiramer acetate is one of the more unusual entries in the UK-licensed peptide set. It is not a single defined sequence. It is a synthetic polypeptide mixture of four amino acids — L-glutamic acid, L-alanine, L-tyrosine and L-lysine — in fixed molar ratios, with a molar mass distribution rather than one molecular weight. That heterogeneity is why regulators treat it as a non-biological complex drug rather than a conventional biological.
Mechanism, stated honestly
The mechanism is not fully established. The literature describes binding to major histocompatibility complex molecules, competition with myelin basic protein, a shift in T-cell populations towards regulatory phenotypes, and possible neuroprotective effects. This page states that uncertainty rather than resolving it.
The UK licensing picture
Glatiramer acetate (Copaxone, with generic versions such as Brabio) holds a UK marketing authorisation for the treatment of relapsing forms of multiple sclerosis. NICE technology appraisal TA527 recommends it as an option for relapsing-remitting multiple sclerosis. It is a prescription-only medicine, supplied through the licensed medicines route.
What the evidence shows
The 1995 phase III trial reported by Johnson and colleagues found a lower annualised relapse rate with glatiramer acetate than with placebo. The UK multiple sclerosis risk-sharing scheme followed patients for ten years; the final results reported by Palace and colleagues in 2019 described outcomes consistent with sustained benefit over that period. Evidence grade: Strong for relapse reduction in relapsing-remitting disease; weaker, and more contested, for disability progression.
Why it belongs in the reference
Glatiramer acetate is a reminder that the word peptide describes a structure, not a regulatory category. Some peptides are licensed UK medicines with randomised human datasets; most compounds on this site are research reagents with no marketing authorisation and no human trial record. Nothing here is a protocol or an instruction for human use.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.